Pliant Therapeutics Inc (STU:9PT)
€ 12.5 -0.7 (-5.3%) Market Cap: 778.32 Mil Enterprise Value: 448.21 Mil PE Ratio: 0 PB Ratio: 2.37 GF Score: 36/100

Pliant Therapeutics Inc to Discuss Results from INTEGRIS-IPF Call Transcript

Jul 11, 2022 / 12:00PM GMT
Release Date Price: €20 (+133.92%)
Christopher Keenan
Pliant Therapeutics, Inc. - Vice President, Investor Relations & Corporate Communications

Good morning, everyone. Thank you for joining us for Pliant's presentation of top line data from the INTEGRIS-IPF Phase 2 clinical trial evaluating PLN-74809 in patients with IPF. The press release that we will be referencing today is available under the Investors & Media section of our corporate website. The slides accompanying this web presentation will be available in the same section of our website following the conclusion of this call.

During today's call, we will be making forward-looking statements, including those related to the therapeutic potential of PLN-74809 and our plans for the future development of PLN-74809. Because forward-looking statements relate to the future, they are subject to inherent uncertainties and risks that are difficult to predict, and many of which are outside of our control. Important risks and uncertainties are set forth in our filings with the SEC, which are available at sec.gov. Pliant undertakes no obligation to update any forward-looking

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot